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phorylated by MK2. MK2 not only transmits p38 signal-Activating MAP KAP Kinase 2
ing to downstream components of the p38 MAP kinase
pathway, it also determines the cellular location of p38.
MK2 has a nuclear localization signal close to its car-
boxyl terminus and a nuclear export signal that is partThe crystal structures of MAP KAP kinase 2 in complex
of the autoinhibitory domain (Engel et al., 1998; Ben-with ADP and staurosporine suggest a major reorgani-
Levy et al., 1998). The crystal structure of the autoinhib-zation of the glycine-rich loop upon ligand binding.
ited MK2 revealed how the protein deals with those twoThe main determinant for the catalytic activity of MAP
signals (Meng et al., 2002). In nonstressed cells, theKAP kinase 2 is phosphorylation by p38 MAP kinase.
autoinhibitory domain binds in the substrate binding
groove of the MK2 catalytic domain. In this state, theAnti-inflammatory therapy is a multibillion-dollar global
nuclear export signal is buried between the catalyticmarket that has received significant attention from the
and autoinhibitory domains, but the nuclear localizationpharmaceutical industry. The COX-2 inhibitors Celebrex
signal is exposed. When the cell undergoes stress, MK2and Vioxx were a major improvement in the treatment
and p38 migrate to the cytoplasm. This migration, how-of rheumatoid arthritis, and worldwide sales of the two
ever, occurs only when p38 is catalytically active. Thedrugs are expected to reach $9.5 billion in 2005 (Renfrey
key event here is the phosphorylation of MK2 residueet al., 2003). Not surprisingly, other anti-inflammatory
334, which is located at the N-terminal end of the autoin-targets are actively being pursued. The p38 mitogen-
hibitory domain. Phosphorylation at this residue, to-activated protein (MAP) kinase pathway plays an impor-
gether with the phosphorylation of T222 in the activationtant role in inflammation (Salituro et al., 1999). Several
loop of MK2 by p38, is thought to release the autoinhibi-inhibitors of p38 MAP kinase are in clinical trials for the
tory domain and expose the nuclear export signal. Cata-treatment of inflammation, acute coronary syndrome,
lytically incompetent mutant p38 or inhibited p38 willrheumatoid arthritis, chronic obstructive pulmonary syn-
prevent the MK2-p38 complex from moving to the cyto-drome, and psoriasis. MAP KAP kinase 2 (MK2) is also
plasm (Ben-Levy et al., 1998). Because the catalytic ac-a member of the p38 MAP kinase pathway, with p38
tivity of p38 is required to respond to stress, it is impor-MAP kinase as its main cellular activator. The p38/MK2
tant to note that the activators of p38, MKK3, and MKK6pathway mediates stress response and is activated by
are localized in the nucleus and cytoplasm. This is inheat shock, UV, lipopolysaccharides, and pro-inflamma-
contrast to the MEK1/ERK signaling route, where MEK1tory cytokines (Cuenda et al., 1995).
is confined to the cytoplasm and activated ERK movesA knockout study in mice provided important proof
from the cytoplasm to the nucleus.that MK2 is a potential target for anti-inflammatory ther-
MK2 is not the only kinase whose catalytic activity isapy (Kotlyarov et al., 1999). More than 50% of knockout
regulated by a C-terminal autoinhibitory segment. Cal-
mice survived endotoxic shock with LPS/galactosamine
cium/calmodulin-dependent kinase-I (cAMK-I), titin ki-
in comparison to only 11% of wild-type mice. The MK2/
nase domain, and twitchen kinase domain also have a
mice release lower levels of the pro-inflammatory cyto- C-terminal tail that folds on the kinase domain and inhib-
kines TNF-, IL-1, IL-6, IL-10, and IFN-. The regulation its the catalytic activity of the kinases (Goldberg et al.,
of the levels of these cytokines and other proteins such 1996; Mayans et al., 1998; Kobe et al., 1996). In all those
as COX-2 is at the mRNA level but involves different instances, the autoinhibitory segment consists of multi-
mechanisms. The amount of TNF- is regulated through ple helices that at least partially block the substrate
translational control via the AU-rich elements of the 3- binding groove. In the case of cAMK-I, the C-terminal
UTR of TNF-mRNA (Neininger et al., 2002). MK2 signal- end of the autoinhibitory domain also binds the glycine-
ing increases TNF- mRNA translation. In the case of rich loop of the  strand domain, blocking the entrance
IL-6, COX-2, and macrophage inflammatory protein 2, of the ATP binding site. For the titin and twitchen kinase
MK2 signaling leads to increased mRNA stability (Winzen domains, part of the autoinhibitory segment occupies
et al., 1999; Lasa et al., 2000; Neininger et al., 2002). the ATP binding site. A short helical segment sits under
MK2 is located in the nucleus, but moves rapidly to the glycine-rich loop, preventing ATP from binding. For
the cytoplasm after stimulation (Engel et al., 1998; Ben- MK2, the autoinhibitory domain mimics substrate bind-
Levy et al., 1998). It has substrates both in the nucleus ing and completely occupies the substrate binding
(CREB; Tan et al., 1996) and in the cytoplasm (leukocyte- groove. In order for these kinases to become catalyti-
specific protein-1 and heat shock proteins HSP25/27; cally active, the autoinhibitory domain must be dissoci-
Huang et al., 1997; Stokoe et al., 1992). A recently dis- ated from the kinase domain. This is a two-step activa-
covered substrate of MK2 is heterogeneous nuclear ri- tion process for all four kinases. For CaMK-1, titin
bonucleoprotein A0 (hnRNP A0) (Rousseau et al., 2002). kinase, and twitchen kinase, the first step is the binding
This protein was captured from the extracts of a murine of Ca/calmodulin to the autoinhibitory domain. The sec-
macrophage-like cell line using the AU-rich element of ond step is the phosphorylation of an activation loop
TNF-mRNA and is therefore a direct link between MK2 residue on the kinase domain. For MK2, the first step
and pro-inflammatory cytokine response. HnRNP A0 is the phosphorylation of T334 at the far N-terminal end
also binds the AU-rich elements of MIP-2 and COX-2, of the autoinhibition segment followed by phosphoryla-
tion of T222 on the activation loop.and the binding is enhanced when hnRNP A0 is phos-
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tors that recognize diverse ligands on target cells. TheA Growing Family
dominant signal received by an NK cell through its inter-of Natural Killers action with normal levels of major histocompatibility
complex class I (MHC-I) molecules on target cells is
inhibitory. When the level of MHC-I is reduced through
infectious or tumorigenic processes, this inhibitory sig-
The structure of the natural cytotoxicity receptor nal is attenuated, and the NK cell is triggered through
NKp44, described in this issue of Structure, adds to its activating receptors, which include NKp44. In this
our rapidly expanding knowledge of the structure of way, diseased cells with abnormal MHC-I expression
natural killer cell receptors, which play a key role in the become the targets of NK lytic activity resulting from
elimination of virally infected and tumor cells during the loss of inhibition of NK cell activation.
innate immune responses. NK receptors belong to two structurally distinct fami-
lies comprising C-type lectin-like domain-containing
Natural killer (NK) cells are a fundamental component molecules with type II membrane topology (e.g., Ly49s,
of the innate immune system that participate in the early NKG2D, CD94/NKG2, NKR-P1, CD69), and proteins dis-
detection and destruction of virally infected and tumor playing an immunoglobulin (Ig) fold with type I mem-
cells (Biron et al., 1999). The cytolytic activity of NK brane topology (e.g., KIRs, LIRs, NKp46, 2B4) (Natarajan
cells is regulated through a delicate balance between et al., 2002). Both the C-type lectin-like and Ig-like fami-
lies include inhibitory and activating receptors. Some ofinhibitory and stimulatory signals delivered by NK recep-
